Dietary supplement

Lore & Background

Dietary supplements are defined under U.S. law by the Dietary Supplement Health and Education Act of 1994 as products intended to supplement the diet that contain one or more dietary ingredients, such as vitamins, minerals, herbs, amino acids, or other dietary substances. They must be labeled as dietary supplements, intended for ingestion, and cannot be represented as conventional food or a sole item of a meal. Unlike drugs, no government approval is required to make or sell supplements; manufacturers themselves confirm safety, and the FDA can only remove unsafe products from the market. Supplements are consumed orally and exclude products like nasal sprays or topical lotions, and FDA-approved drugs cannot be ingredients in them.

Reader's Guide

Dietary supplements play a significant role in public health and commerce, particularly in the United States where the industry was valued at $151.9 billion in 2021 and over 95,000 products are marketed. About 60% of American adults consume them, with multivitamins being the most common. The U.S. National Institutes of Health notes that some supplements may help provide essential nutrients or support health for those with limited dietary variety. However, federal regulations prohibit manufacturers from claiming that supplements prevent or treat any disease; only structure/function claims are allowed with a disclaimer that the FDA has not evaluated the claim. The FDA enforces safety and good manufacturing practices. In the European Union, harmonized rules ensure safety and appropriate labeling. The definition under DSHEA classifies supplements as food, not drugs, and they can include synthetic copies of natural substances like melatonin. Despite their popularity, evidence of benefit for healthy individuals with adequate diets is limited, and products may exceed tolerable upper intake levels set by the U.S. Institute of Medicine.

Did You Know?

• The U.S. supplement industry was valued at approximately $56.7 billion in 2021.
• About 74% of Americans over age 60 consume dietary supplements.
• Multivitamins are the most commonly used type of dietary supplement.
• Under U.S. law, supplement labels must include a disclaimer that the FDA has not evaluated structure/function claims.

Legislative Origins and Industry Lobbying

In the late 1980s and early 1990s, the U.S. Congress was weighing legislation that would have expanded the FDA's regulatory reach over the supplement market. The Nutrition Advertising Coordination Act of 1991, which proposed stricter rules on supplement labeling, triggered a fierce lobbying campaign from health food companies. These firms warned consumers that the FDA intended to ban dietary supplements entirely, and one widely circulated advertisement depicted actor Mel Gibson being raided and arrested by federal agents simply for taking vitamin C pills. Gerald Kessler, CEO of Nature Plus and a driving force behind the lobbying push, publicly charged the FDA with maintaining a decades-long bias against the supplement industry. The political pressure culminated when Senator Orrin Hatch of Utah and Senator Tom Harkin of Iowa co-sponsored the Dietary Supplement Health and Education Act. President Bill Clinton signed the legislation into law on October 25, 1994, praising what he called a conscientious alliance among manufacturers, nutrition experts, and legislators. Notably, Hatch's campaign drew significant financial backing from multi-level marketing companies such as XanGo and Herbalife.

What Qualifies as a Dietary Supplement

DSHEA draws a precise legal boundary around what counts as a dietary supplement. The statute defines the category as any product, excluding tobacco, that is designed to augment the normal diet and contains at least one dietary ingredient. Eligible ingredients span vitamins, minerals, herbs and other botanicals, amino acids, dietary substances meant to boost overall intake, as well as concentrates, metabolites, constituents, extracts, or any combination of these. Beyond composition, the law imposes structural requirements: the product must carry a label identifying it as a dietary supplement, it must be intended for ingestion, and it cannot be marketed as a conventional food item or as the sole component of a meal. The act also establishes a critical legal distinction—supplements are classified as food for virtually all regulatory purposes, but they are carved out of the drug definition. This means a supplement cannot simultaneously be approved or authorized as a new drug, antibiotic, or biologic, unless it had already been sold as a food or supplement before that drug authorization was sought.

Labeling and Disclosure Requirements

The act prescribes a detailed checklist of information that must appear on every dietary supplement container. A label, defined as any written, printed, or graphic display on the packaging, must include a statement of identity containing the words dietary supplement, though dietary may be replaced by the ingredient name, as in ginseng supplement. The net quantity of contents, such as 60 capsules, is mandatory, and a Supplement Facts panel must list the serving size, the amount of each dietary ingredient, and the percent daily value where established. Products containing proprietary blends must disclose the blend's net weight and list every component in descending order by weight. For herbal or botanical ingredients, the specific part of the plant used must be identified. The label must also carry the manufacturer's or distributor's name and business address, a full ingredient list by common names, and any safety information deemed material to potential consequences of use. When a product makes a structure or function claim, a general well-being claim, or a claim tied to a classical nutrient deficiency disease, the mandatory FDA disclaimer must appear, stating the product has not been evaluated and is not intended to diagnose, treat, cure, or prevent disease. Manufacturers retain discretion to add further claims or quality-assurance statements and to decide their placement.

Regulatory Gaps and Ongoing Controversies

One of DSHEA's most consequential provisions is its grandfathering clause: supplements already on the U.S. market before 1994 require no FDA approval before continued sale. Ingredients not covered by that exemption are classified as New Dietary Ingredients under 21 U.S.C. 350b(d) and must be the subject of a notification providing reasonable evidence of safety, which the FDA reviews but does not approve. The agency is explicitly barred from approving any supplement for safety or effectiveness. The herbal industry has pushed back against this limited review, arguing it undermines the law's original intent to grant the sector freedom to market products as food. Manufacturers have routinely and systematically sidestepped the New Dietary Ingredient process by first adding a new compound to a food product, self-certifying its safety under the generally recognized as safe framework, and only then introducing it into a supplement. Critics point to scarce public safety data on supplements and an insufficient FDA network for tracking adverse events. A 2010 bill mandating tracking of illnesses linked to supplement use was blocked by Senator Hatch. Manufacturers have welcomed the act, framing it as a protection of consumer access regardless of whether a product's efficacy has been demonstrated.